BOOTS COUGH AND DECONGESTANT SYRUP 6 YEARS +
Active substance: PSEUDOEPHEDRINE HYDROCHLORIDE
View full screen / Print PDF » Download PDF ⇩
Transcript
SUMMARY OF PRODUCT CHARACTERISTICS
1
NAME OF THE MEDICINAL PRODUCT
Boots Cough and Decongestant Syrup 6 Years +
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION Active ingredient Guaifenesin Pseudoephedrine hydrochloride % w/v 1.0 0.2
3.
PHARMACEUTICAL FORM Syrup
4
4.1
CLINICAL PARTICULARS
Therapeutic indications
A combination expectorant and decongestant for the relief of acute productive (chesty) cough, nasal congestion and congestion of the mucous membranes of the upper respiratory tract associated with the common cold.
4.2
Posology and method of administration For oral administration. Children 6 to 12 years: Two 5ml spoonfuls three or four times a day. Not more than 4 doses should be given in any 24 hours. This medicine is contraindicated in children under 6 years of age (see section 4.3). Children of 6-12 years of age: not to be used for more than 5 days without the advice of a doctor. Parents and carers should seek medical attention if the child's condition deteriorates during treatment.
Warning: Do not exceed the stated dose. Keep all medicines out of the sight and reach of children.
4.3
Contraindications Hypersensitivity to the active substances or any of the excipients or intolerance to other sympathomimetics. Severe renal impairment Cardiovascular disease including hypertension and peripheral vascular disease. Diabetes mellitus Phaeochromocytoma Hyperthyroidism Closed angle glaucoma Concomitant use of other sympathomimetic decongestants Monoamine oxidase inhibitors (MAOIs), or within 14 days of stopping treatment (see section 4.5). Beta-blockers (see section 4.5). Not to be used in children under the age of 6 years.
4.4
Special warnings and precautions for use Guaifenesin Ask a doctor before use if you suffer from a chronic cough, if you have asthma or are suffering from an acute asthma attack. Stop use and ask a healthcare professional if your cough lasts for more than 5 days, comes back, or is accompanied by a fever, rash, or persistent headache. Do not take with a cough suppressant. Pseudoephedrine If any of the following occur, this medicine should be stopped Hallucinations Restlessness Sleep disturbances Caution in moderate to severe renal impairment. Pseudoephedrine should be used with caution when administered to patients taking antihypertensive agents, tricyclic antidepressants, other sympathomimetic agents such as decongestants, appetite suppressants and amphetamine-like psycho-stimulants. The effects of a single dose on the blood pressure of these patients should be observed before recommending repeated or unsupervised treatment.
Do not give with any other cough and cold medicine. If symptoms do not go away, talk to your pharmacist or doctor. 4.5 Interaction with other medicinal products and other forms of interaction Pseudoephedrine MAOIs and/or RIMAs: should not be given to patients treated with MAOIs or within 14 days of stopping treatment: increased risk of hypertensive crisis. Moclobemide: risk of hypertensive crisis. Antihypertensives: (including adrenergic neurone blockers, diuretics & betablockers): pseudoephedrine may block the hypotensive effects. Cardiac glycosides: increased risk of dysrhythmias. Ergot alkaloids (ergotamine & methysergide): increased risk of ergotism. Appetite suppressants and amphetamine-like psycho-stimulants: risk of hypertension. Oxytocin: risk of hypertension. Enhances effects of anticholinergic drugs (such as TCAs). Should not be given with other sympathomimetics such as decongestants, and thyroid hormones. Should not be given to patients undergoing general anaesthesia as them may induce ventricular arrhythmias. Guaifenesin If urine is collected within 24 hours of a dose of guaifenesin a metabolite of guaifenesin may cause a colour interference with laboratory determinations of urinary 5-hydroxyindoleacetic acid (5-HIAA) and vanillylmandelic acid (VMA).
4.6.
Pregnancy and Lactation Since the product is intended only for use in children, information on its use in pregnancy and lactation is not relevant.
4.7.
Effects on Ability to Drive and Use Machines No adverse effects known.
4.8
Undesirable effects Guaifenesin
The following side effects may be associated with the use of guaifenesin: Gastrointestinal disorders: nausea, vomiting, gastrointestinal discomfort. Immune system disorders: hypersensitivity reactions.
Pseudoephedrine Cardiovascular disorders: tachycardia, palpitations, other cardiac dysrythmias. Gastrointestinal disorders: nausea and/or vomiting, dry mouth. General disorders and administration site conditions: irritability, thirst, tolerance with dependence has been reported with prolonged administration of pseudoephedrine-containing preparations. Immune system disorders: hypersensitivity reactions, including crosssensitivity that may occur with other sympathomimetics. Musculoskeletal and connective tissue disorders: muscular weakness. Nervous system disorders: headache, giddiness, tremor, anxiety, restlessness, excitability, insomnia, hallucinations (particularly in children) and paranoid delusions. Psychiatric disorders: sleep disturbance. Renal and urinary disorders: difficulty in micturition including urinary retention. Skin and subcutaneous tissue disorders: skin reactions including rash, sweating. Vascular disorders: hypertension. 4.9. Overdose Symptoms of overdosage include headache, nausea, vomiting, tachycardia, urinary retention, hallucinations, coma, tremor, excitement, convulsions, respiratory depression, hypertension and arrhythmias. Initial treatment consists of either emesis or gastric lavage, if appropriate. Otherwise treatment should by symptomatic and supportive, including the administration of a beta blocker if supraventricular tachycardia supervenes.
5. 5.1.
PHARMACOLOGICAL PROPERTIES Pharmacodynamic Properties Pseudoephedrine acts directly on both alpha and to a lesser extent beta adrenergic receptors. It is believed that the alpha adrenergic effects result from inhibition of the production of cyclic AMP by inhibition of the enzyme adenyl cyclase, whereas beta adrenergic effects result from stimulation of adenyl cyclase activity. Pseudoephedrine also has an indirect effect by releasing noradrenaline from its storage sites.
Guaifenesin reduces the viscosity of tenacious sputum and is used as an expectorant.
5.2.
Pharmacokinetic Properties Pseudoephedrine is absorbed from the gastrointestinal tract. It is resistant to metabolism by monoamine oxidase and is largely excreted unchanged in the urine together with small amounts of its hepatic metabolite. It has an elimination half life of several hours. Guaifenesin is readily absorbed from the gastrointestinal tract. it is metabolised and excreted in the urine.
5.3.
Pre-clinical Safety Data Not applicable.
6
6.1
PHARMACEUTICAL PARTICULARS
List of excipients Maltitol liquid Hydroxyethyl cellulose Glycerin Purified water Potassium sorbate Acesulfame K Sodium citrate Citric acid monohydrate Levomenthol Alcohol 96% Blackcurrant flavour Vanilla bean extract
6.2.
Incompatibilities None stated.
6.3.
Shelf-Life 24 months.
6.4
Special precautions for storage
Do not store above 25C.
6.5.
Nature and Content of Container Amber PET bottle with polypropylene child resistant closure fitted with an expanded polyethylene liner. Pack size: 100ml, 125ml, 150ml, 200ml
6.6.
Instructions for Use, Handling and Disposal Not applicable.
7.
MARKETING AUTHORISATION HOLDER The Boots Company PLC 1 Thane Road West Nottingham NG2 3AA England
8.
MARKETING AUTHORISATION NUMBER(S) PL 0014/0545
9
DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION
31/01/1997 / 21/12/2001
10
DATE OF REVISION OF THE TEXT
07/09/2012
1
NAME OF THE MEDICINAL PRODUCT
Boots Cough and Decongestant Syrup 6 Years +
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION Active ingredient Guaifenesin Pseudoephedrine hydrochloride % w/v 1.0 0.2
3.
PHARMACEUTICAL FORM Syrup
4
4.1
CLINICAL PARTICULARS
Therapeutic indications
A combination expectorant and decongestant for the relief of acute productive (chesty) cough, nasal congestion and congestion of the mucous membranes of the upper respiratory tract associated with the common cold.
4.2
Posology and method of administration For oral administration. Children 6 to 12 years: Two 5ml spoonfuls three or four times a day. Not more than 4 doses should be given in any 24 hours. This medicine is contraindicated in children under 6 years of age (see section 4.3). Children of 6-12 years of age: not to be used for more than 5 days without the advice of a doctor. Parents and carers should seek medical attention if the child's condition deteriorates during treatment.
Warning: Do not exceed the stated dose. Keep all medicines out of the sight and reach of children.
4.3
Contraindications Hypersensitivity to the active substances or any of the excipients or intolerance to other sympathomimetics. Severe renal impairment Cardiovascular disease including hypertension and peripheral vascular disease. Diabetes mellitus Phaeochromocytoma Hyperthyroidism Closed angle glaucoma Concomitant use of other sympathomimetic decongestants Monoamine oxidase inhibitors (MAOIs), or within 14 days of stopping treatment (see section 4.5). Beta-blockers (see section 4.5). Not to be used in children under the age of 6 years.
4.4
Special warnings and precautions for use Guaifenesin Ask a doctor before use if you suffer from a chronic cough, if you have asthma or are suffering from an acute asthma attack. Stop use and ask a healthcare professional if your cough lasts for more than 5 days, comes back, or is accompanied by a fever, rash, or persistent headache. Do not take with a cough suppressant. Pseudoephedrine If any of the following occur, this medicine should be stopped Hallucinations Restlessness Sleep disturbances Caution in moderate to severe renal impairment. Pseudoephedrine should be used with caution when administered to patients taking antihypertensive agents, tricyclic antidepressants, other sympathomimetic agents such as decongestants, appetite suppressants and amphetamine-like psycho-stimulants. The effects of a single dose on the blood pressure of these patients should be observed before recommending repeated or unsupervised treatment.
Do not give with any other cough and cold medicine. If symptoms do not go away, talk to your pharmacist or doctor. 4.5 Interaction with other medicinal products and other forms of interaction Pseudoephedrine MAOIs and/or RIMAs: should not be given to patients treated with MAOIs or within 14 days of stopping treatment: increased risk of hypertensive crisis. Moclobemide: risk of hypertensive crisis. Antihypertensives: (including adrenergic neurone blockers, diuretics & betablockers): pseudoephedrine may block the hypotensive effects. Cardiac glycosides: increased risk of dysrhythmias. Ergot alkaloids (ergotamine & methysergide): increased risk of ergotism. Appetite suppressants and amphetamine-like psycho-stimulants: risk of hypertension. Oxytocin: risk of hypertension. Enhances effects of anticholinergic drugs (such as TCAs). Should not be given with other sympathomimetics such as decongestants, and thyroid hormones. Should not be given to patients undergoing general anaesthesia as them may induce ventricular arrhythmias. Guaifenesin If urine is collected within 24 hours of a dose of guaifenesin a metabolite of guaifenesin may cause a colour interference with laboratory determinations of urinary 5-hydroxyindoleacetic acid (5-HIAA) and vanillylmandelic acid (VMA).
4.6.
Pregnancy and Lactation Since the product is intended only for use in children, information on its use in pregnancy and lactation is not relevant.
4.7.
Effects on Ability to Drive and Use Machines No adverse effects known.
4.8
Undesirable effects Guaifenesin
The following side effects may be associated with the use of guaifenesin: Gastrointestinal disorders: nausea, vomiting, gastrointestinal discomfort. Immune system disorders: hypersensitivity reactions.
Pseudoephedrine Cardiovascular disorders: tachycardia, palpitations, other cardiac dysrythmias. Gastrointestinal disorders: nausea and/or vomiting, dry mouth. General disorders and administration site conditions: irritability, thirst, tolerance with dependence has been reported with prolonged administration of pseudoephedrine-containing preparations. Immune system disorders: hypersensitivity reactions, including crosssensitivity that may occur with other sympathomimetics. Musculoskeletal and connective tissue disorders: muscular weakness. Nervous system disorders: headache, giddiness, tremor, anxiety, restlessness, excitability, insomnia, hallucinations (particularly in children) and paranoid delusions. Psychiatric disorders: sleep disturbance. Renal and urinary disorders: difficulty in micturition including urinary retention. Skin and subcutaneous tissue disorders: skin reactions including rash, sweating. Vascular disorders: hypertension. 4.9. Overdose Symptoms of overdosage include headache, nausea, vomiting, tachycardia, urinary retention, hallucinations, coma, tremor, excitement, convulsions, respiratory depression, hypertension and arrhythmias. Initial treatment consists of either emesis or gastric lavage, if appropriate. Otherwise treatment should by symptomatic and supportive, including the administration of a beta blocker if supraventricular tachycardia supervenes.
5. 5.1.
PHARMACOLOGICAL PROPERTIES Pharmacodynamic Properties Pseudoephedrine acts directly on both alpha and to a lesser extent beta adrenergic receptors. It is believed that the alpha adrenergic effects result from inhibition of the production of cyclic AMP by inhibition of the enzyme adenyl cyclase, whereas beta adrenergic effects result from stimulation of adenyl cyclase activity. Pseudoephedrine also has an indirect effect by releasing noradrenaline from its storage sites.
Guaifenesin reduces the viscosity of tenacious sputum and is used as an expectorant.
5.2.
Pharmacokinetic Properties Pseudoephedrine is absorbed from the gastrointestinal tract. It is resistant to metabolism by monoamine oxidase and is largely excreted unchanged in the urine together with small amounts of its hepatic metabolite. It has an elimination half life of several hours. Guaifenesin is readily absorbed from the gastrointestinal tract. it is metabolised and excreted in the urine.
5.3.
Pre-clinical Safety Data Not applicable.
6
6.1
PHARMACEUTICAL PARTICULARS
List of excipients Maltitol liquid Hydroxyethyl cellulose Glycerin Purified water Potassium sorbate Acesulfame K Sodium citrate Citric acid monohydrate Levomenthol Alcohol 96% Blackcurrant flavour Vanilla bean extract
6.2.
Incompatibilities None stated.
6.3.
Shelf-Life 24 months.
6.4
Special precautions for storage
Do not store above 25C.
6.5.
Nature and Content of Container Amber PET bottle with polypropylene child resistant closure fitted with an expanded polyethylene liner. Pack size: 100ml, 125ml, 150ml, 200ml
6.6.
Instructions for Use, Handling and Disposal Not applicable.
7.
MARKETING AUTHORISATION HOLDER The Boots Company PLC 1 Thane Road West Nottingham NG2 3AA England
8.
MARKETING AUTHORISATION NUMBER(S) PL 0014/0545
9
DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION
31/01/1997 / 21/12/2001
10
DATE OF REVISION OF THE TEXT
07/09/2012
Source: Medicines and Healthcare Products Regulatory Agency
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
